Go to the page content
Obesity

A Study on How NNC0174-1213 Works in People With Overweight or Obesity.

Locations

United States

Start date

03/12/2024

Identifiers

Trial ID NN9839-8082,
NCT number NCT06719011,
Eudract number Not Available

Summary

This study is testing a new study medicine to treat people living with overweight or obesity. The aim of this study is to see if the medicine is safe, how it works in human body, and what human body does to the study medicine. Participants will either get the new study medicine NNC0174-1213, a study medicine called "cagrilintide" or a placebo (a "dummy medicine" similar to the new study medicine and study medicine but without active ingredients). Which treatment participants will get is decided by chance. The new study medicine and the study medicine are potential new medicines which cannot be prescribed by doctors. This study will last for about a year in total.

Trial Overview:

Condition

Obesity

Overweight

Treatment

DRUG: NNC0174-1213 A

DRUG: Cagrilintide B

DRUG: Placebo A (NNC0174 1213 A)

Study type

INTERVENTIONAL

Trial duration

Dec 03 2024 - Mar 26 2026

Participants

177

Phase

I

Are you eligible?

Gender

MALE

Age

18 to 55 years old

Questions or concerns

Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.

This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.